Review articlePublished 2014

Endogenous Opioids and the Treatment of Multiple Sclerosis

Authors: Ian S. Zagon, Patricia J. McLaughlin

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Multiple sclerosis is an autoimmune disorder of the central nervous system that affects approximately 400,000 people in the United States and 2 million individuals worldwide. The disease is chronic, often progressive, and manifests through proliferation and activation of T-lymphocytes and astrocytes, resulting in demyelination and axonal damage. Approved therapies are interferon-based or involve T-cell immune modulators; however, many treatments have unacceptable side-effects, are cost-prohibitive, and/or require clinical visits for administration. There is an unmet need for disease-modifying therapies that are non-toxic and readily available. The regulatory pathway involving opioid growth factor (OGF) and its nuclear-associated receptor, OGFr, is involved in several autoimmune diseases including multiple sclerosis. The OGF-OGFr axis appears to be aberrant in that patients with autoimmune disorders often have reduced levels of peptide, an inhibitory growth factor targeting cell proliferation.OGF is an endogenous neuropeptide, chemically termed [Met5]-enkephalin, that ameliorates the course of experimental autoimmune encephalomyelitis when treatment is initiated at the time of induction in mouse models of progressive disease. OGF therapy initiated at the time of disease presentation reversed progressive disease within one week. OGF treatment of the mouse model of relapse-remitting experimental autoimmune encephalomyelitis resulted in a significant reduction in the severity and number of relapses. Treatment with OGF of established relapse-remitting disease diminished peak clinical disease and suppressed relapses. Preclinical studies, as well as clinical observations, support the use of endogenous opioids as safe and effective disease-modifying biotherapeutics.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

More from this journal

The newest in Journal of Neurology & Neurophysiology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Neurology & Neurophysiology
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Ian S. Zagon”
  • BylineArticles whose byline prints “Patricia J. McLaughlin”